Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 195

1.

Safety and efficacy of turoctocog alfa in the prevention and treatment of bleeds in previously untreated paediatric patients with severe haemophilia A: Results from the guardian 4 multinational clinical trial.

Yaish H, Matsushita T, Belhani M, Jiménez-Yuste V, Kavakli K, Korsholm L, Matytsina I, Philipp C, Reichwald K, Wu R.

Haemophilia. 2019 Dec 9. doi: 10.1111/hae.13883. [Epub ahead of print]

PMID:
31816159
2.

A comparative study of pneumomediastinums based on clinical experience.

Sapmaz E, Işık H, Doğan D, Kavaklı K, Çaylak H.

Ulus Travma Acil Cerrahi Derg. 2019 Aug;25(5):497-502. doi: 10.14744/tjtes.2019.03161.

3.

Subcutaneous concizumab prophylaxis in hemophilia A and hemophilia A/B with inhibitors: phase 2 trial results.

Shapiro AD, Angchaisuksiri P, Astermark J, Benson G, Castaman G, Chowdary P, Eichler H, Jiménez-Yuste V, Kavakli K, Matsushita T, Poulsen LH, Wheeler AP, Young G, Zupancic-Salek S, Oldenburg J.

Blood. 2019 Nov 28;134(22):1973-1982. doi: 10.1182/blood.2019001542.

PMID:
31444162
4.

Bodyweight-adjusted rivaroxaban for children with venous thromboembolism (EINSTEIN-Jr): results from three multicentre, single-arm, phase 2 studies.

Monagle P, Lensing AWA, Thelen K, Martinelli I, Male C, Santamaría A, Samochatova E, Kumar R, Holzhauer S, Saracco P, Simioni P, Robertson J, Grangl G, Halton J, Connor P, Young G, Molinari AC, Nowak-Göttl U, Kenet G, Kapsa S, Willmann S, Pap AF, Becka M, Twomey T, Beyer-Westendorf J, Prins MH, Kubitza D; EINSTEIN-Jr Phase 2 Investigators.

Lancet Haematol. 2019 Oct;6(10):e500-e509. doi: 10.1016/S2352-3026(19)30161-9. Epub 2019 Aug 13.

PMID:
31420317
5.

Evaluation of Bleeding Phenotype of Inherited Factor VII Deficiency in Children With a Bleeding Assessment Tool and Global Assays.

Toret E, Ay Y, Karapinar TH, Oymak Y, Kavakli K, Vergin RC.

J Pediatr Hematol Oncol. 2019 Jul 23. doi: 10.1097/MPH.0000000000001564. [Epub ahead of print]

PMID:
31343480
6.

Using pharmacokinetics for tailoring prophylaxis in people with hemophilia switching between clotting factor products: A scoping review.

Yu JK, Iorio A, Edginton AN; WAPPS co‐investigators.

Res Pract Thromb Haemost. 2019 May 20;3(3):528-541. doi: 10.1002/rth2.12204. eCollection 2019 Jul. Review. Erratum in: Res Pract Thromb Haemost. 2019 Sep 16;3(4):771.

7.

Fertility in Patients with Thalassemia and Outcome of Pregnancies: A Turkish Experience

Akıncı B, Yaşar AŞ, Özdemir Karadaş N, Önder Siviş Z, Hekimci Özdemir H, Yılmaz Karapınar D, Balkan C, Kavaklı K, Aydınok Y.

Turk J Haematol. 2019 Nov 18;36(4):274-277. doi: 10.4274/tjh.galenos.2019.2019.0025. Epub 2019 Jun 14.

8.

Extended Half-Life Coagulation Factors: A New Era in the Management of Hemophilia Patients

Ar MC, Balkan C, Kavaklı K.

Turk J Haematol. 2019 Aug 2;36(3):141-154. doi: 10.4274/tjh.galenos.2019.2018.0393. Epub 2019 May 15.

9.

The impact of psychosocial determinants on caregivers' burden of children with haemophilia (results of the BBC study).

von Mackensen S, Myrin Westesson L, Kavakli K, Klukowska A, Escuriola C, Uitslager N, Santoro C, Holland M, Khair K.

Haemophilia. 2019 May;25(3):424-432. doi: 10.1111/hae.13684. Epub 2019 Apr 11.

PMID:
30974034
10.

The burden of bleeds and other clinical determinants on caregivers of children with haemophilia (the BBC Study).

Khair K, Klukowska A, Myrin Westesson L, Kavakli K, Escuriola C, Uitslager N, Santoro C, Holland M, von Mackensen S.

Haemophilia. 2019 May;25(3):416-423. doi: 10.1111/hae.13736. Epub 2019 Mar 29.

PMID:
30925018
11.

Genotype analysis and identification of novel mutations in a multicentre cohort of patients with hereditary factor X deficiency.

Mitchell M, Gattens M, Kavakli K, Liesner R, Payne J, Norton M, Austin S.

Blood Coagul Fibrinolysis. 2019 Jan;30(1):34-41. doi: 10.1097/MBC.0000000000000787.

PMID:
30507709
12.

Concizumab restores thrombin generation potential in patients with haemophilia: Pharmacokinetic/pharmacodynamic modelling results of concizumab phase 1/1b data.

Eichler H, Angchaisuksiri P, Kavakli K, Knoebl P, Windyga J, Jiménez-Yuste V, Harder Delff P, Chowdary P.

Haemophilia. 2019 Jan;25(1):60-66. doi: 10.1111/hae.13627. Epub 2018 Nov 8.

PMID:
30408848
13.

Long-term safety and efficacy of turoctocog alfa in prophylaxis and treatment of bleeding episodes in severe haemophilia A: Final results from the guardian 2 extension trial.

Lentz SR, Janic D, Kavakli K, Miljic P, Oldenburg J, C Ozelo M, Santagostino E, Suzuki T, Zupancic Šalek S, Korsholm L, Matytsina I, Tiede A.

Haemophilia. 2018 Nov;24(6):e391-e394. doi: 10.1111/hae.13617. Epub 2018 Nov 6.

PMID:
30402994
14.

Phase 3 study of recombinant von Willebrand factor in patients with severe von Willebrand disease who are undergoing elective surgery.

Peyvandi F, Mamaev A, Wang JD, Stasyshyn O, Timofeeva M, Curry N, Cid AR, Yee TT, Kavakli K, Castaman G, Sytkowski A.

J Thromb Haemost. 2019 Jan;17(1):52-62. doi: 10.1111/jth.14313. Epub 2018 Dec 20.

15.

Prospective Evaluation of Non-Compliant Severe Hemophilia Patients

Uğur MC, Kavaklı K.

Turk J Haematol. 2019 May 3;36(2):137-138. doi: 10.4274/tjh.galenos.2018.2018.0281. Epub 2018 Oct 2. No abstract available.

16.

The predictive value of factor VIII/factor IX levels to define the severity of hemophilia: communication from the SSC of ISTH.

Mancuso ME, Bidlingmaier C, Mahlangu JN, Carcao M, Tosetto A; subcommittee on factor viii, factor ix and rare coagulation disorders.

J Thromb Haemost. 2018 Oct;16(10):2106-2110. doi: 10.1111/jth.14257. Epub 2018 Sep 5. No abstract available.

PMID:
30182468
17.

Phase 1, single-dose escalating study of marzeptacog alfa (activated), a recombinant factor VIIa variant, in patients with severe hemophilia.

Gruppo RA, Malan D, Kapocsi J, Nemes L, Hay CRM, Boggio L, Chowdary P, Tagariello G, von Drygalski A, Hua F, Scaramozza M, Arkin S; Marzeptacog alfa (activated) Study Group Investigators.

J Thromb Haemost. 2018 Oct;16(10):1984-1993. doi: 10.1111/jth.14247. Epub 2018 Aug 27.

PMID:
30151972
18.

A randomized trial of safety, pharmacokinetics and pharmacodynamics of concizumab in people with hemophilia A.

Eichler H, Angchaisuksiri P, Kavakli K, Knoebl P, Windyga J, Jiménez-Yuste V, Hyseni A, Friedrich U, Chowdary P.

J Thromb Haemost. 2018 Nov;16(11):2184-2195. doi: 10.1111/jth.14272. Epub 2018 Sep 30.

PMID:
30137664
19.

Common themes and challenges in hemophilia care: a multinational perspective.

Stoffman J, Andersson NG, Branchford B, Batt K, D'Oiron R, Escuriola Ettingshausen C, Hart DP, Jiménez Yuste V, Kavakli K, Mancuso ME, Nogami K, Ramírez C, Wu R.

Hematology. 2019 Dec;24(1):39-48. doi: 10.1080/10245332.2018.1505225. Epub 2018 Aug 3.

PMID:
30073913
20.

Haemophilia clinical care and research needs: Assessing priorities.

Chowdary P, Angchaisuksiri P, Dimsits J, Iorio A, Kavakli K, Lentz SR, Mahlangu J, McCarthy A, Kessler C.

Haemophilia. 2018 Jul;24(4):e270-e273. doi: 10.1111/hae.13544. Epub 2018 Jul 13. No abstract available.

PMID:
30004622

Supplemental Content

Loading ...
Support Center